Advertisement

Evolution of the Synthetic Process to Prepare the Tripeptide Segment of ABT-510

  • Calvin L. Becker
  • Jean Christophe Califano
  • John C. Tolle
  • James J. Napier
  • Lawrence Kolaczkowski
  • Sou-Jen Chang
  • Zhenping Tian
  • Sukamar Manna
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (volume 611)

Introduction

ABT-510 is a thrombospondin-1 mimetic currently in Phase 2 clinical trials as an angiogenesis inhibitor for treatment of cancer. An efficient synthetic process was developed by the Process R&D group at Abbott and has been scaled to produce several 10 kg batches of the drug substance.

Keywords

Reverse Osmosis Ammonium Chloride Catalytic Hydrogenation Thionyl Chloride Hydrophobic Interaction Chromatography 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Calvin L. Becker
    • 1
  • Jean Christophe Califano
    • 1
  • John C. Tolle
    • 1
  • James J. Napier
    • 1
  • Lawrence Kolaczkowski
    • 1
  • Sou-Jen Chang
    • 1
  • Zhenping Tian
    • 1
  • Sukamar Manna
    • 1
  1. 1.GPRD Process Research and DevelopmentAbbott LaboratoriesNorth ChicagoUSA

Personalised recommendations